Search Tufts Medicine

This study is to evaluate Safety & Tolerability of multiple doses of an experimental i.v. medication (called AP-SA02) in Phase 1b and to evaluate Efficacy, Safety & Tolerability of multiple doses of the same experimental medication in Phase 2a, as compared to Placebo in patients with certain bacterial infection (bacteria named Staphylococcus aureus) of your blood stream. The experimental drug or Placebo will be given in addition to any treatment given for the Blood stream infection by Staphylococcus aureus.

It is hypothesized that inhaled RT234 will provide a therapeutic benefit for "as needed" (PRN) use in patients with WHO Group 1 Pulmonary Hypertension (PH) (Pulmonary Arterial Hypertension (PAH)) to improve exercise capacity and therefore performance in activities of daily living as well as reduce exertional symptoms (e.g., dyspnea) and their deleterious impacts on quality of life (QoL).

This is a Phase 2 study investigating safety and tolerability of Inhaled Treprostinil in participants with Pulmonary Hypertension associated with Interstitial Lung Disease.

This is a long-term extension (LTE) follow up study where recruitment of subjects will continue as the parent study (AV-101-002) progresses from Phase 2b to Phase 3. Subjects who were on placebo in Phase 2b and the Intermediate Part of the study who enroll in the LTE study will be re-randomized to one of the 3 active AV-101 doses until such time as the optimal dose has been selected.

This study aims to compare the effects of inhaled isoflurane sedation with the standard of care IV sedative propofol. Patients enrolled on this study will be on a ventilator (breathing machine) for more than 12 hours and require continuous sedation to keep the patient comfortable which can range from a state of drowsiness and relaxtion to a state of unconsciousness.

Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade E, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, efficacy and safety study of subjects with Progressive Pulmonary Fibrosis (PPF) treated with inhaled treprostinil over a 52-week period

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with IPF with or without standard-of-care. Patients meeting the eligibility criteria for the study will be randomized with a 2:1 ratio to DWN12088 150 mg BID or the matching placebo. Randomization will be stratified according to other medications for IPF (patients receiving pirfenidone or nintedanib and patients with no treatment for IPF, with a minimum of 30% of patients on no treatment) and to country (patients in United States or South Korea).

To evaluate the systemic exposure of treprostinil after inhaled administration in subjects with idiopathic pulmonary fibrosis (IPF)

The primary objective of the study is to evaluate the safety and efficacy of inhaled treprostinil in subjects with IPF. This study hypothesizes that inhaled treprostinil will have a positive effect on absolute FVC after 52 weeks of therapy as compared with placebo when administered to subjects with IPF.

This study is designed to evaluate the safety and efficacy of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. 

This is a Phase 3, open-label, follow-up study to evaluate the long-term safety and efficacy of sotatercept when added to background PAH therapy for the treatment of PAH. Participants eligible to enroll in the study will have participated in and completed the relevant study requirements of the PAH sotatercept clinical studies. Participants who have discontinued from a previous PAH sotatercept clinical study will not be eligible to enroll in this LTFU study.

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. The objective of this study is to evaluate the effects of sotatercept treatment (plus maximum tolerated background PAH therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours, in participants with WHO FC III or FC IV PAH at high risk of mortality.

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to background PAH therapy in newly diagnosed intermediate- and high-risk PAH patients.

This is a Phase 3, randomized, double-blinded, placebo-controlled study to compare the efficacy and safety of sotatercept versus placebo when added to background pulmonary arterial hypertension (PAH) therapy for the treatment of PAH. The objective of this study is to evaluate the efficacy and safety of sotatercept treatment (plus background PAH therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with PAH.

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease

This is a study of the prevalence of APOL1 alleles in adults who are of recent African ancestry or geographic origin. The study will enroll up to a total of approximately 2500 subjects into 2 groups. Group 1 includes subjects with FSGS, and Group 2 includes subjects with other forms of proteinuric nondiabetic CKD. No study drug will be administered.

Patients with Chronic Kidney Disease(CKD) who receive medical care at Tufts Medicine will be invited to join a CKD research registry. The registry will record their medical information related to CKD and future researchers will be allowed to contact patients to ask if they would like to join a CKD related research study. There is nothing patients have to do once they join the registry, and joining a CKD research study is entirely optional.

The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. 

The study will consist of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.

Patients receiving maintenence hemodialysis will be screened for underlying cognitive impairment using the Montreal Cognitive Assessment (MoCA) Tool, a cognitive screening tool. Routine dialysis data, including biochemical measures and attendance records, will then be subsequently examined. Depending on the MoCA results, patients may be invited to participate in an interview to explore their experience with the MoCA screening tool and other aspects of their dialysis care.